Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia.

about

Domain II of Pseudomonas Exotoxin Is Critical for Efficacy of Bolus Doses in a Xenograft Model of Acute Lymphoblastic Leukemia.

P2860

Q55420593-50E77245-B6D1-4F33-A9DE-1F17F96CAC70

P2860

Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia.

Item

http://www.wikidata.org/entity/Q46385489

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Phase 1 study of the anti-CD22 ...... acute lymphoblastic leukemia.

@en

Phase 1 study of the anti-CD22 ...... acute lymphoblastic leukemia.

@nl

type

Item

label

Phase 1 study of the anti-CD22 ...... acute lymphoblastic leukemia.

@en

Phase 1 study of the anti-CD22 ...... acute lymphoblastic leukemia.

@nl

prefLabel

Phase 1 study of the anti-CD22 ...... acute lymphoblastic leukemia.

@en

Phase 1 study of the anti-CD22 ...... acute lymphoblastic leukemia.

@nl

P1476

Phase 1 study of the anti-CD22 ...... acute lymphoblastic leukemia.

@en

P2093

Alan S Wayne

http://www.w3.org/2001/XMLSchema#string

Deepa Bhojwani

http://www.w3.org/2001/XMLSchema#string

Ira Pastan

http://www.w3.org/2001/XMLSchema#string

James A Whitlock

http://www.w3.org/2001/XMLSchema#string

Jie Yang

http://www.w3.org/2001/XMLSchema#string

Lewis B Silverman

http://www.w3.org/2001/XMLSchema#string

Mark C Lanasa

http://www.w3.org/2001/XMLSchema#string

Maryalice Stetler-Stevenson

http://www.w3.org/2001/XMLSchema#string

Meina Liang

http://www.w3.org/2001/XMLSchema#string

Nirali N Shah

http://www.w3.org/2001/XMLSchema#string

P2860

A new paradigm: Diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury

Chimeric antigen receptor T cells for sustained remissions in leukemia

Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display.

Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia.

Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study.

Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial

NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantatio

Chronic health conditions in adult survivors of childhood cancer.

Characterization of CD22 expression in acute lymphoblastic leukemia

Immunotoxin resistance via reversible methylation of the DPH4 promoter is a unique survival strategy.

P304

1620-1627

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2017-02-749101

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

130

http://www.w3.org/2001/XMLSchema#string

P577

2017-08-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28983018

http://www.w3.org/2001/XMLSchema#string

P921

leukemia

P932

5630009

http://www.w3.org/2001/XMLSchema#string

Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia.

about

P2860

P2860

Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921

P932